---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-293485"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2026-07-02T12:00:40+00:00"
generated_at: "2026-07-02T12:05:06.398338+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August

## Summary
- Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).
- Company expects to report topline data in August 2026; database lock and statistical analysis underway.
- Trial evaluates TNX-103 (oral levosimendan) in PH-HFpEF; enrollment of >230 patients completed March 2026.
- BSSR in Dec 2025 showed >90% power to detect 25m change in 6MWD primary endpoint.

## SEC filing metadata
- accession: 0001193125-26-293485
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2026-07-02T12:00:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/0001193125-26-293485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/d20457d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-293485
- JSON: https://secwatch.observer/filing/0001193125-26-293485.json
- Plain text: https://secwatch.observer/filing/0001193125-26-293485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.